Pacira Biosciences Inc (PCRX) Inventory Turnover Ratio, from second quarter 2026 to second quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Pacira Biosciences inc   (NASDAQ: PCRX)
 

Pacira Biosciences Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Pacira Biosciences Inc inventory turnover ratio, the Pacira Biosciences Inc 's ability to sell and replace its inventory in the second quarter 2026, sequentially increased to 1.04 in the second quarter 2026, yet the ratio remained below the average, as PCRX's market remain challenging.Average inventory processing period, for the Pacira Biosciences Inc in Jun 30 2026 quarter, has decreased to 351 days, compare to 365 days, in the Mar 31 2026 quarter.

Within Healthcare sector 308 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 658 in the first quarter 2026, to 1797.

PCRX Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Pacira Biosciences Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PCRX Inventory Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Inventory Growth -9.17 % 12.42 % 22.02 % 40.96 % 43.24 %
Y / Y Cost of Sales Growth 8.07 % 6.14 % 1.04 % -11.8 % -7.67 %
Inventory Turnover Ratio (TTM) 1.04 1 1.01 1.06 1.19
PCRX's Total Ranking # 1797 # 658 # 1291 # 1139 # 1359
Average inventory processing period 350 366 361 345 308
Seq. Inventory Growth -10.5 % -1.63 % -3.05 % 6.42 % 10.77 %
Seq. Cost of Sales Growth 21.29 % -9.64 % 17.57 % -16.12 % 19.12 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 89
Healthcare Sector # 309
Overall Market # 1797

Inventory Turnover Ratio Statistics
High Average Low
6.21 2.37 0.97
(Dec 31 2014)   (Dec 31 2025)



PCRX Company Profile >> Back to PCRX Efficiency Comparisons >> Compare PCRX Inventory Turnover Ratio to its Competitors

Financial Statements
Pacira Biosciences Inc 's Inventories $ 135 Millions Visit PCRX's Balance sheet
Pacira Biosciences Inc 's Cost of Revenues TTM $ 155 Millions Visit PCRX's Income Statement
What are PCRX's Sales? Visit PCRX's Sales by Segment

Other Inventory Turnover Ratios
Pacira Biosciences Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
PCRX's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for PCRX's Competitors
Inventory Turnover Ratio for PCRX's Suppliers
Inventory Turnover Ratio for PCRX's Customers

You may also want to know
PCRX's Sales Growth Rates PCRX's Pe Price to earnings ratio PCRX's Receivables Turnover Ratio PCRX's Stock Quote
PCRX's Net Income Growth Rates PCRX's Ps Price to Sales ratio PCRX's Sales per Employee PCRX's Asset Turnover Ratio
PCRX's Net Margin PCRX's Pb Price to Book ratio PCRX's Financial Strength Ratios PCRX's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Jun 30 2026 Inventories at quarter ending Jun 30 2026
Bionexus Gene Lab Corp   3.15 $ 2.362  Millions$ 1  Millions
Zevra Therapeutics Inc   3.14 $ 6.180  Millions$ 2  Millions
Prestige Consumer Healthcare Inc   3.13 $ 513.522  Millions$ 164  Millions
Eton Pharmaceuticals Inc   3.11 $ 44.176  Millions$ 14  Millions
Mimedx Group Inc   3.07 $ 75.981  Millions$ 25  Millions
Revvity Inc  2.98 $ 1,136.473  Millions$ 381  Millions
Amneal Pharmaceuticals Inc   2.98 $ 1,891.689  Millions$ 635  Millions
Akebia Therapeutics Inc   2.96 $ 44.632  Millions$ 15  Millions
Msa Safety Inc  2.92 $ 1,021.036  Millions$ 350  Millions
Ligand Pharmaceuticals Incorporated  2.91 $ 32.387  Millions$ 11  Millions
Logicmark Inc  2.83 $ 3.881  Millions$ 1  Millions
Iovance Biotherapeutics inc   2.81 $ 152.872  Millions$ 54  Millions
Dexcom Inc   2.81 $ 1,864.400  Millions$ 663  Millions
Livanova Plc  2.79 $ 468.065  Millions$ 168  Millions
Merck and Co Inc   2.79 $ 17,996.000  Millions$ 6,447  Millions
Inspiremd Inc   2.78 $ 8.847  Millions$ 3  Millions
Dentsply Sirona Inc   2.77 $ 1,839.000  Millions$ 663  Millions
Ani Pharmaceuticals Inc  2.69 $ 387.398  Millions$ 144  Millions
Neogen Corporation  2.67 $ 461.474  Millions$ 173  Millions
Innoviva Inc   2.65 $ 102.975  Millions$ 39  Millions
International Stem Cell Corporation  2.61 $ 4.285  Millions$ 2  Millions
Biomerica Inc   2.59 $ 4.091  Millions$ 2  Millions
Evofem Biosciences Inc   2.58 $ 4.418  Millions$ 2  Millions
Indivior Pharmaceuticals Inc   2.55 $ 240.000  Millions$ 94  Millions
Nephros Inc   2.54 $ 8.991  Millions$ 4  Millions
Illumina Inc   2.52 $ 1,510.000  Millions$ 599  Millions
IMPACT BIOMEDICAL INC.  2.46 $ 0.414  Millions$ 0  Millions
Quidelortho Corp  2.45 $ 1,481.500  Millions$ 605  Millions
Cumberland Pharmaceuticals Inc   2.44 $ 5.164  Millions$ 2  Millions
Perrigo Company Plc  2.43 $ 2,775.900  Millions$ 1,140  Millions

Date modified: 2026-09-26T06:58:04+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.